• Dr Richard Mead
    Dr Richard Mead PhD

    Richard Mead is a Senior Lecturer (associate professor) at the Sheffield Institute for Translational Neuroscience. He has 16 years’ experience in preclinical drug discovery in academia and industry and has a track record of taking compounds through preclinical programs to nomination for clinical development. He has worked on the target pathway (NRF2-KEAP1) for over 8 years and taken a reactive Nrf2 activator from screening to orphan designation with the EMA for MND. He is a named inventor on 4 patents and has attracted funding of £7.4M as primary investigator and co-investigator.

  • Tom Bartlett
    Tom Bartlett PhD

    Tom Bartlett is Business Manager within the Sheffield Healthcare Gateway where he manages Industrial collaborations.  He was previously at the Centre for Drug Research and Development (CDRD), Vancouver where he was part of the team that identifies and evaluates new technologies across a broad range of therapeutic areas including neurology, psychiatry, anti-infectives and oncology. Thomas has a BSc in biochemistry and a PhD in neuroscience from the University of Bristol. While completing his academic training, Thomas also worked for a year in the Pain Biology group at Pfizer Global R&D.

  • Alan Naylor
    Alan Naylor PhD

    Alan Naylor is a medicinal chemist with over 30 years experience in Research and Development within GlaxoSmithKline. He previously held the position of Vice President and Director of Medicinal Chemistry within the GSK Drug Discovery organization and has lead strategic, matrix and line functions involving significant international responsibilities. He has an extensive track record of success, across a wide range of therapeutic areas, having played a major role in the discovery of over 30 development compounds, and is a co-inventor of Serevent, a major advance in the treatment of asthma.

    As an independent consultant, Alan provides scientific and strategic advice and analysis to major pharma, biotechnology companies, academic groups, capital investment companies and funding bodies.

  • Janusz Kulagowski
    Janusz Kulagowski PhD

    Jan Kulagowski is Drug Discovery Manager at Parkinson’s UK, With over 30 years experience in drug discovery research as a medicinal chemist, Jan has worked in neuroscience with Merck Sharp and Dohme and, more recently, in a variety of therapeutic areas including oncology, inflammation and respiratory disease with the integrated drug discovery services provider Argenta Discovery (now Discovery at Charles River). He obtained his B.Sc and Ph.D from Imperial College, held a NATO postdoctoral position at Stanford University and is author or inventor on over 150 scientific publications and patents.